Publications associées à Dyskinésie tardive

Depotentiation of associative plasticity is intact in Parkinson's disease with mild dyskinesia

Objective: Depotentiation of homosynaptic plasticity of the primary motor cortex (M1) is impaired in patients with Parkinson's disease (PD) who have developed dyskinesias. In this exploratory study, we tested whether this holds true for heterosynaptic plas ...

ELSEVIER SCI LTD2022

The shine-through paradigm and the schizophrenia spectrum: a summary

Michael Herzog, Simona Adele Garobbio, Maya Roinishvili, Ophélie Gladys Favrod, Janir Nuno Ramos Antunes Da Cruz

In the past 10 years, our laboratory has proved the shine-through paradigm to be a very sensitive endophenotype for schizophrenia. The shine-through paradigm is a visual backward masking task, where the target is a vertical vernier followed by a 25-element ...

2021

Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease

Salvatore Novello

To investigate whether the reversible MAO-B inhibitor and sodium channel blocker safinamide impairs glutamate release under parkinsonian conditions in vivo, and this effect is dependent on MAO-B inhibition, safinamide (and rasagiline as a comparator) were ...

PERGAMON-ELSEVIER SCIENCE LTD2020

Psychotropic drug-induced genetic-epigenetic modulation of CRTC1 gene is associated with early weight gain in a prospective study of psychiatric patients

Johannes Gräff, Jose Vicente Sanchez Mut, Aurélie Delacrétaz, Céline Dubath

Background: Metabolic side effects induced by psychotropic drugs represent a major health issue in psychiatry. CREB-regulated transcription coactivator 1 (CRTC1) gene plays a major role in the regulation of energy homeostasis and epigenetic mechanisms may ...

2019

Mining the Potential of Label-Free Biosensors for In Vitro Antipsychotic Drug Screening

Sandro Carrara, Tugba Kilic, Hatice Altug, Maria Soler Aznar

The pharmaceutical industry is facing enormous challenges due to high drug attribution rates. For the past decades, novel methods have been developed for safety and efficacy testing, as well as for improving early development stages. In vitro screening met ...

2018

Inhaling xenon ameliorates l -dopa-induced dyskinesia in experimental parkinsonism

Grégoire Courtine, Eduardo Martin Moraud, Tomislav Milekovic, Shiqi Sun

Parkinson's disease motor symptoms are treated with levodopa, but long‐term treatment leads to disabling dyskinesia. Altered synaptic transmission and maladaptive plasticity of corticostriatal glutamatergic projections play a critical role in the pathophys ...

2018

A novel psychoanalytical approach: An electrochemical ligand-binding assay to screen antipsychotics

Sandro Carrara, Tugba Kilic

Schizophrenia treatment may see a paradigm shift due to development of new atypical antipsychotic drugs (APDs), with better tolerability due to more selective dopamine (DA) receptor blockade. Monitoring of these APD candidates in biological fluids is of gr ...

2018

Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments

Pierre Magistretti, Aurélie Delacrétaz

Weight gain is a major health problem among psychiatric populations. It implicates several receptors and hormones involved in energy balance and metabolism. Phosphoenolpyruvate carboxykinase 1 is a rate-controlling enzyme involved in gluconeogenesis, glyce ...

Lippincott, Williams & Wilkins2015

Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments

Pierre Magistretti, Murielle Bochud, Aurélie Delacrétaz

Background Metabolic syndrome (MetS) associated with psychiatric disorders and psychotropic treatments represents a major health issue. 11 beta-Hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) is an enzyme that catalyzes tissue regeneration of active cor ...

Lippincott Williams & Wilkins2015